Liquid-biopsy cancer diagnostics
| Filer | 13FScore | This quarter | Shares | Value | % of their book |
|---|---|---|---|---|---|
| Ancora | 42 | New buy | 6 | $1,070 | 0.0% |
| Paul Tudor Jones / Tudor | 61 | New buy | 109,440 | $19,519,718 | 0.0% |
| Steve Cohen / Point72 | 75 | Trimmed -34% | 637,905 | $113,776,736 | 0.1% |
| Bridgewater | 55 | Trimmed -2% | 4,159 | $741,799 | 0.0% |
| Trade date | Who | Type | Amount | |
|---|---|---|---|---|
| 2026-09-28 | Jonathan Jackson IL01 | BUY | $15,001 - $50,000 | PTR |
| Report | Date | Stance |
|---|---|---|
| #84 — Market Memo: Healthcare's AI-Powered Trump Card | 2025-02-09 | LONG |
Every tracked holder of this name, sorted new → added → flat → trimmed. Shares = reported 13F share count; Value as reported (a few managers file values in $thousands). Generated 2026-11-17.